Imunon Stock (NASDAQ:IMNN)
Previous Close
$1.14
52W Range
$0.48 - $3.65
50D Avg
$1.24
200D Avg
$1.08
Market Cap
$16.42M
Avg Vol (3M)
$3.07M
Beta
2.13
Div Yield
-
IMNN Company Profile
Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.
IMNN Performance
Peer Comparison
| Ticker | Company |
|---|---|
| SNTI | Senti Biosciences, Inc. |
| BLCM | Bellicum Pharmaceuticals, Inc. |
| CYCC | Cyclacel Pharmaceuticals, Inc. |
| XCUR | Exicure, Inc. |
| HSTO | Histogen Inc. |
| SABS | SAB Biotherapeutics, Inc. |
| LSTA | Lisata Therapeutics, Inc. |
| LIXT | Lixte Biotechnology Holdings, Inc. |
| TOVX | Theriva Biologics, Inc. |
| QNRX | Quoin Pharmaceuticals, Ltd. |
| DFFN | CervoMed Inc. |
| HILS | Tharimmune, Inc. |
| CING | Cingulate Inc. |
| KA | Kineta, Inc. |
| AVTX | Avalo Therapeutics, Inc. |
| DMAC | DiaMedica Therapeutics Inc. |
| NLTX | Neurogene Inc. |
| CBIO | Gyre Therapeutics, Inc. |
| LUMO | Lumos Pharma, Inc. |